by John R. Fischer
, Senior Reporter | February 04, 2020
Best Medical International and Best Particle Therapy of TeamBest Companies plan to install the first rapid cycling medical synchrotron in the world at the University of Wisconsin Medical Radiation Research Center, to deliver carbon therapy.
The companies and university signed a memorandum of understanding last month for the introduction of Best Particle Therapy’s 400 MeV Rapid Cycling Medical Synchrotron (iRCMS), the very first of which will be assembled, tested and used at UWMRRC. It will be used to help many patients, primarily ones from Midwest states such as Illinois, Wisconsin, and Indiana.
"We are excited and proud to have UWMRRC partner with us in introducing this highly advanced carbon Therapy for very accurate treatment of tumors ... Our goal is to make this affordable and accessible globally," Krishnan Suthanthiran, president and founder of TeamBest, told HCB News.
The iRCMS offers variable energy, heavy ion treatment technologies for proton-to-carbon heavy ion. This enables clinicians to apply precise, conformal and hypo-fractionated radiation therapy in the treatment of their patients.
The technology also offers intrinsically small beams to help facilitate beam delivery, with precision for the most conformal radiation therapy; small beam size for a smaller footprint due to the solution’s small magnets and light gantries; highly efficient single-turn extraction for less shielding; and flexibility for heavy ion beam therapy using protons and carbon, and beam delivery modalities.
TeamBest Companies is also working with Best Cure Foundation to establish a Hub-and-Spoke Model of Healthcare Delivery System. The model will comprise Express and Mobile clinics that will be connected to general and multi-specialty medical centers with access to all of TeamBest’s new and advanced technologies worldwide.
Best Medical International recently teamed up with another TestBest company, Best Cyclotron Systems, to build a new enterprise called Best ABT. The company was established through the acquisition of Tennessee-based cyclotron manufacturer ABT Molecular Imaging
, which equipped it with greater expertise on smaller cyclotron technology, including ABT Molecular Imaging’s BG-75 Biomarker Generator, and automated chemistry for delivering greater-quality oncology diagnoses and care to a large group of currently underserved patients worldwide.
“Now we can offer a range of cyclotrons for medical radioisotope production and research, with 7.5, 15, 20, 25, 30, 35 and 70 MeV cyclotrons, and 400 MeV rapid cycling medical synchrotrons for heavy ion particle therapy from proton, to carbon heavy ion radiation therapy, revolutionizing cancer treatment,” said Suthanthiran at the time.
The technology is currently being developed and tested at Brookhaven National Labs.
Manufacturing, assembling and testing of the entire system will take two to three years.